AviadoBio

Translating groundbreaking science and precision delivery into life-changing medicines for people living with devastating neurodegenerative diseases.

[AviadoBio @AviadoBio]

We’re thrilled to announce our new exclusive option-license agreement with UgeneX Therapeutics for UGX-202, a novel, investigational #GeneTherapy designed to potentially restore vision in people living with #RetinitisPigmentosa and other retinal diseases. https://t.co/257U6gpZpq

[AviadoBio @AviadoBio]

What does it take to develop transformative gene therapies for neurodegenerative diseases?

Our CEO Lisa Deschamps spoke with Onyx Newsroom to share her perspective on what's behind AviadoBio's recent momentum and where we're headed next.

Watch now: https://t.co/1LWth89uzU

[AviadoBio @AviadoBio]

Our Chief Scientific and Clinical Advisor and Co-founder Chris Shaw is speaking in two sessions this week at the ALS Drug Development Summit in Boston — one on in vitro platforms for ALS drug development, and one on gene silencing approaches for ALS.

https://t.co/PbGFhALRYk

[AviadoBio @AviadoBio]

Healthy Vision Month is a powerful reminder of how urgently treatments are needed for those living with retinal diseases like retinitis pigmentosa (RP).

At AviadoBio, we're committed to relentlessly chasing cures through the potential of gene therapy for diseases like RP.

[AviadoBio @AviadoBio]

AviadoBio is at FTD UK 2026 tomorrow, joining leaders across the field to advance the conversation on frontotemporal dementia.

We’re excited to connect with researchers, clinicians, and advocates in the discussions shaping the future of FTD treatment.

#FrontotemporalDementia

[AviadoBio @AviadoBio]

Did you know?

This week is Dementia Action Week – a time to recognize and raise awareness for those living with this devastating disease, including frontotemporal dementia (FTD) which remains widely misunderstood and misdiagnosed.

Learn more: https://t.co/fIOQaKNAOO

[AviadoBio @AviadoBio]

We’re leaving ASGCT 2026 energized after connecting with leaders across the gene therapy community and presenting new preclinical data for our AVB-406 program in Alzheimer’s disease and other tauopathies.

Read more about the data here: https://t.co/dBbsB1nYIg

@ASGCTherapy

[AviadoBio @AviadoBio]

Today, we announced positive preclinical data for our AVB-406 program at ASGCT 2026, supporting our plans to advance AVB-406 into clinical trials for Alzheimer's disease by the end of the year.

Read more about the data here: https://t.co/dBbsB1nYIg

@ASGCTherapy #GeneTherapy

[AviadoBio @AviadoBio]

This week marks the start of #ASGCT2026.

We look forward to connecting with the broader CGT community and presenting data on AVB-406 and our proprietary vMiX™ RNAi platform.

If you’re attending ASGCT, let’s connect.

#GeneTherapy @ASGCTherapy

[AviadoBio @AviadoBio]

We’re looking forward to sharing more about our proprietary vMiX™ RNAi gene silencing platform at #ASGCT2026.

vMiX is designed for potent and tolerable gene silencing, enabling new approaches to precision gene therapy for neurodegenerative diseases.

​​Learn more ↓

[AviadoBio @AviadoBio]

Thank you to everyone who made the AFTD Education Conference 2026 so meaningful.

We’re grateful for the opportunity to connect with patients, families, and advocates, and to hear firsthand the experiences that continue to shape and inspire our work at AviadoBio.

@AFTDHope

[AviadoBio @AviadoBio]

Our CEO, Lisa Deschamps, is on the ground at Bio€quity Europe 2026, where she’ll be joining “The Race for Speed” panel discussing how European biotechs can accelerate to compete and lead in today’s global landscape.

Don’t miss this discussion tonight at 6:30 PM CET.
@BioCentury

[AviadoBio @AviadoBio]

📍We’re onsite at the AFTD Education Conference 2026.

There’s nothing more powerful than coming together with the FTD community united by a shared commitment to progress.

If you’re here, come say hello!

#AFTD2026 @AFTDHope #FrontotemporalDementia

[AviadoBio @AviadoBio]

Today, we announced our agreement with Apertura to license TfR1 CapX™, a novel capsid we'll leverage to advance investigational one-time genetic medicines for neurodegenerative diseases, including AVB-406 in Alzheimer’s & related tauopathies.

Learn more: https://t.co/mP7i4LxkKF

[AviadoBio @AviadoBio]

Our Chief Technology Officer, Alex Bloom, is speaking on Tuesday at the Cell & Gene Therapy Summit at ChinaBio about navigating investigator-initiated trials in China for gene therapy development.

Interested in attending? Learn more: https://t.co/ZJf7UbMifX

#GeneTherapy

[AviadoBio @AviadoBio]

Next week, our CEO Lisa Deschamps will join the “Ethics and ATMPs” panel at Meeting on the Med to explore the evolving ATMP landscape with other industry leaders.

Learn more about the panel: https://t.co/YU1H848FKJ

#MeetingOnTheMed #Biotech

[AviadoBio @AviadoBio]

We’re heading to ASGCT 2026 next month!

We look forward to engaging in meaningful discussions, sharing insights, and continuing to push the boundaries of what’s possible in gene therapy.

Also attending? Contact us.

@ASGCTherapy #ASGCT26 #GeneTherapy #Biotech

[AviadoBio @AviadoBio]

We’re looking forward to attending the AFTD Education Conference 2026 this month as we connect with patients, families, advocates, and the broader FTD community — learning and sharing the progress we’re making together.

If you’re attending, we’d love to connect.

@AFTDHope

[AviadoBio @AviadoBio]

Did you know?

RP is a leading cause of visual disability & blindness, yet there are no treatments for late-stage photoreceptor loss.

We're working to change that by advancing AVB-307, an intravitreally-delivered AAV #optogenetic investigational therapy.

https://t.co/yqbKPP9iwZ

[AviadoBio @AviadoBio]

Breakthrough science starts with the right people. We believe building a team fueled by purpose and relentlessness drives real progress, especially when tackling big challenges.

Learn more from CEO Lisa Deschamps on what drives #TeamAviadoBio.

#BiotechTeams

[AviadoBio @AviadoBio]

Congratulations to Senior Research Associate, Debs Ojutalayo, on being named Rising Star at the Black Professionals in Life Sciences (#BPLS) Inspire Awards 2026. We’re proud to see her recognized for her leadership and commitment to innovation and inclusion in UK life sciences.